Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) EBT (2016 - 2025)

CorMedix's EBT history spans 14 years, with the latest figure at $56.4 million for Q4 2025.

  • For Q4 2025, EBT rose 350.88% year-over-year to $56.4 million; the TTM value through Dec 2025 reached $150.0 million, up 840.09%, while the annual FY2025 figure was $150.0 million, 886.82% up from the prior year.
  • EBT for Q4 2025 was $56.4 million at CorMedix, up from $52.6 million in the prior quarter.
  • Across five years, EBT topped out at $56.4 million in Q4 2025 and bottomed at -$15.9 million in Q1 2024.
  • The 5-year median for EBT is -$7.2 million (2021), against an average of $2.0 million.
  • The largest annual shift saw EBT crashed 50.44% in 2023 before it skyrocketed 1993.4% in 2025.
  • A 5-year view of EBT shows it stood at -$7.8 million in 2021, then decreased by 5.44% to -$8.2 million in 2022, then dropped by 18.11% to -$9.7 million in 2023, then soared by 229.04% to $12.5 million in 2024, then skyrocketed by 350.88% to $56.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's EBT are $56.4 million (Q4 2025), $52.6 million (Q3 2025), and $20.3 million (Q2 2025).